Chemically Modified RNA Delivery for Bone Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutics for fracture healing and bone regeneration, such as recombinant bone morphogenetic protein-2 (BMP-2), face challenges including high costs and the need for supraphysiological dosages due to short half-lives, as well as safety concerns with viral and non-viral gene delivery systems, which limit their clinical translation.
Innovation Solution
A delivery system using chemically modified RNA (cmRNA) encoded with BMP-2 or other morphogenetic proteins, delivered via non-viral vehicles encapsulated in biocompatible scaffolds, which eliminates the need for nuclear trafficking and reduces immunogenicity, allowing for controlled release and enhanced transfection efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant BMP-2 protein is used for bone regeneration, then bone healing effectiveness is improved, but cost and dosage requirements increase due to short half-life
Solution Approach 1:
The patent changes the molecular form from protein to nucleic acid (DNA/RNA), fundamentally altering the pharmacokinetic parameters. This allows the therapeutic to be produced endogenously by the patient's cells, eliminating the need for repeated supraphysiological dosing and extending the effective duration of action.
Solution Approach 2:
Instead of delivering the protein directly, the patent delivers the genetic instructions (DNA/RNA) that enable patient cells to copy and produce the BMP-2 protein themselves. This self-replicating approach ensures sustained production at physiological levels without requiring continuous external administration.
2Productivity
If viral vectors are used for gene delivery, then transfection efficiency is improved, but safety concerns and immunogenicity increase
Solution Approach 1:
The patent extracts the essential function of viral vectors (nucleic acid delivery) while removing the harmful viral components. By using non-viral delivery systems such as liposomes, polymers, or naked nucleic acid, the invention achieves transfection without triggering the immune response associated with viral proteins.
Solution Approach 2:
The patent employs transient, non-integrating nucleic acid delivery systems that provide short-term expression without permanent genomic integration. This disposable approach using plasmid DNA or mRNA avoids the safety concerns of viral integration while maintaining sufficient transfection efficiency for therapeutic effect.
3Reliability
If non-viral gene delivery vectors are used, then safety is improved, but transfection efficiency decreases
Solution Approach 1:
The patent employs composite delivery systems combining nucleic acid with non-viral carriers such as cationic lipids, polymers, or nanoparticles. These composite structures protect the nucleic acid from degradation, enhance cellular uptake, and improve transfection efficiency while maintaining the safety advantages of non-viral systems.
Solution Approach 2:
The patent optimizes physical and chemical parameters of non-viral delivery systems, including particle size, surface charge, and nucleic acid formulation, to enhance cellular uptake and transfection efficiency. By adjusting these parameters, the invention achieves safe and effective delivery without requiring viral vectors.
4Duration of action of stationary object
If DNA-based gene therapy is used, then sustained protein production is improved, but nuclear trafficking requirements create barriers in non-dividing cells
Solution Approach 1:
The patent inverts the traditional DNA→protein pathway by using RNA (particularly mRNA) as the direct therapeutic agent. This eliminates the need for nuclear import and integration, allowing cytoplasmic translation to occur directly in non-dividing cells while maintaining sustained protein production capability.
Solution Approach 2:
The patent extracts the nuclear trafficking requirement from the gene delivery process by using mRNA instead of DNA. This removes the barrier posed by the nuclear envelope in non-dividing cells while preserving the ability to sustain protein production through continuous translation of the cytoplasmic mRNA.
Data Source
AI summary
The present disclosure provides compositions and methods useful for tissue engineering including a composition having chemically modified RNA (cmRNA) encapsulated in or complexed with a non-viral delivery vehicle and a biocompatible, bioresorbable scaffold and methods of using the composition to regenerate, for example, bone tissue.